European Union - English - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - vaccines - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).the use of dengvaxia should be in accordance with official recommendations.

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - dengue-yellow fever chimeric virus serotype 1 live (attenuated) antigen (unii: 75kb2hpx5h) (dengue-yellow fever chimeric virus serotype 1 live (attenuated) antigen - unii:75kb2hpx5h), dengue-yellow fever chimeric virus serotype 2 live (attenuated) antigen (unii: fh5svg7glc) (dengue-yellow fever chimeric virus serotype 2 live (attenuated) antigen - unii:fh5svg7glc), dengue-yellow fever chimeric virus serotype 3 live (attenuated) antigen (unii: rht2q37fyg) (dengue-yellow fever chimeric virus serotype 3 liv - dengvaxia® (dengue tetravalent vaccine, live) is a vaccine indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3, and 4. dengvaxia is approved for use in individuals 6 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas. limitations of use - dengvaxia is not approved for use in individuals younger than 6 years of age. these individuals, regardless of previous infection by dengue virus, are at increased risk of severe and hospitalized dengue disease following vaccination with dengvaxia and subsequent infection with any dengue virus serotype. [see warnings and precautions (5.1).] - dengvaxia is not approved for use in individuals not previously infected by any dengue virus serotype or for whom this information is unknown. those not previously infected are at increased risk for severe dengue disease when vaccinated and subsequently infected with dengue virus. [see warnings and precautions (5.1).] previous dengue infection c

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - chimeric yellow fever dengue virus serotype 1, quantity: 6 ccid50; chimeric yellow fever dengue virus serotype 2, quantity: 6 ccid50; chimeric yellow fever dengue virus serotype 3, quantity: 6 ccid50; chimeric yellow fever dengue virus serotype 4, quantity: 6 ccid50 - suspension, powder for - excipient ingredients: cystine; tyrosine; arginine hydrochloride; histidine; isoleucine; leucine; lysine hydrochloride; methionine; phenylalanine; threonine; tryptophan; alanine; asparagine; aspartic acid; glutamic acid; proline; serine; glycine; sucrose; trehalose dihydrate; sorbitol; trometamol; urea; valine - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 9 through 45 years of age living in endemic areas. use should be in accordance with official guidelines (see dosage and administration).

Singapore - English - HSA (Health Sciences Authority)

merck pte. ltd. - cetuximab, chimeric antibody - infusion, solution - 5mg/ml - cetuximab, chimeric antibody 5mg/ml

United Kingdom - English - VMD (Veterinary Medicines Directorate)

msd animal health uk limited - chimeric flavivirus - suspension for injection - inactivated viral vaccine - horses

European Union - English - EMA (European Medicines Agency)

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivated viral and inactivated bacterial vaccines - pigs - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.for active immunisation of pigs over the age of 3 weeks against mycoplasma hyopneumoniae to reduce lung lesions caused by infection with m. hyopneumoniae.

European Union - English - EMA (European Medicines Agency)

roche registration gmbh - tocilizumab - arthritis, rheumatoid; arthritis, juvenile rheumatoid; cytokine release syndrome; giant cell arteritis; covid-19 virus infection - immunosuppressants - roactemra, in combination with methotrexate (mtx), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx.  roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of giant cell arteritis (gca) in adult patients.roactemra, in combination with methotrexate (mtx), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.roactemra, in combination with methotrexate (mtx), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. roactemra has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.roactemra is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.roactemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 2 years of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. roactemra can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.roactemra in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. roactemra can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.roactemra is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.

European Union - English - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - lymphoma, mantle-cell - antineoplastic agents - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor.acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

European Union - English - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologicals for suidae - pigs (for fattening) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d.active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

European Union - English - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - immunosuppressants - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx.- the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists.in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate.tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx.tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx.tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate.tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older.tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.